The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs ... Sacramento Bee Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease – the ... |
